NeuroPace, Inc. (NPCE) Research
NeuroPace, Inc. is a U.S.-based medical technology firm. It specializes in the creation and distribution of the RNS system, an advanced brain-responsive neuromodulation device designed to manage medically intractable focal epilepsy. This innovative system delivers tailored, real-time therapy directly to the source of seizures. Furthermore, the RNS system continuously records brain activity, providing medical professionals with the capability to monitor patients both on-site and remotely. The company supplies its devices to hospitals for both initial surgical implantations and subsequent replacement procedures. NeuroPace, Inc. was founded in 1997 and maintains its corporate headquarters in Mountain View, California.
Market snapshot
- Symbol
- NPCE
- Price
- $15.63
- Day change
- +3.10%
- Market cap
- $532.9M
- P/E ratio
- -24.44x
- 52-week range
- 7.563-19.6
- Sector
- Healthcare
- Industry
- Medical - Devices
- Next earnings
- in 2 months
- Analyst price target
- $20.00
Peer companies
Recent insider activity
- Huennekens R Scott — A-Award (5368 shares) on 2026-06-05
- Huennekens R Scott — A-Award (2890 shares) on 2026-06-05
- Fischer Frank M — A-Award (2890 shares) on 2026-06-05
- Fischer Frank M — A-Award (5368 shares) on 2026-06-05
- Geiger Uri — A-Award (2890 shares) on 2026-06-05
Open NeuroPace, Inc. (NPCE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.